
Contents

List of Contributors, vii

Preface, xi

Part I: Investigating the Liver

- 1** Non-invasive markers of liver fibrosis: useful or useless?, 3
Pierre Bedossa
- 2** Liver biopsy in hepatitis C patients with easy-to-treat characteristics: should we bother or just do biomarkers?, 6
Michelle Lai, Nezam Afzal
- 3** Screening for hepatocellular carcinoma in viral liver disease: is ultrasound enough?, 9
Amit G. Singal, Jorge A. Marrero
- 4** Genomic investigations in viral hepatitis: likely to help or hinder?, 13
Guohong Deng, Yasser El sherif, Mark R. Thursz
- 5** Affective and cognitive disorders in hepatitis C infection: are they real and what are the mechanisms?, 19
Markus Gess, Daniel M. Forton, Howard C. Thomas, Simon D. Taylor-Robinson

Part II: Today's Therapies

Section 1: HCV

- 6** Acute hepatitis: treat immediately or give a chance to spontaneously clear?, 29
Ranjeeta Bahirwani, David E. Kaplan
- 7** Management of HCV genotype 1 non-responders/relapsers: a European perspective, 34
Harald Farnik, Stefan Zeuzem
- 8** HCV genotype 1: how are you managing the non-responders and relapsers? A North American perspective, 38
Michael W. Fried
- 9** Management of HCV-2 and HCV-3 non-responders and relapsers, 43
Giada Sebastiani, Alfredo Alberti
- 10** Management of HCV infection in patients with thalassemia and sickle cell disease, 47
Paul Telfer, Banu Kaya
- 11** Management of HCV in dialysis patients, 50
Fabrizio Fabrizi, Paul Martin
- 12** Management of HCV in patients with a renal transplant, 55
Richard Marley, Janet Dearden
- 13** Management of HCV in patients with psychiatric comorbidity, 58
Alexander Evans, William Rosenberg
- 14** Morbid obesity and HCV: management strategies, 61
Venessa Pattullo, Jenny Heathcote
- 15** Management of cytopenias during chronic hepatitis C therapy, 65
Alyson N. Fox, Vinod K. Rustgi
- 16** Management of patients with multiple HCV genotypes, 70
Peter Ferenci
- 17** HCV and injecting drug users: how do we approach them?, 73
Olav Dalgard
- 18** HCV with and without autoimmune features: how do you sort them out and manage?, 76
M. Shadab Siddiqui, Steven L. Flamm
- 19** HCV and iron excess: the interaction and how to handle it, 82
Bryan D. Maliken, Kris V. Kowdley
- 20** Management of patients with genotype 3 chronic hepatitis C: can we change the duration of therapy?, 88
Alessandra Mangia, Valeria Piazzolla, Angelo Andriulli
- 21** Management of hepatitis C in children, 94
Maureen M. Jonas

- 22** Controlling symptoms in chronic HCV on and off treatment: does anything work?, 99
Brenda A. Appolo
- 23** Complementary therapies in chronic HCV: exploitation or something to offer?, 105
Kelly C. Vranas, K. Rajender Reddy
- 24** HCV in liver transplant recipients: how do you approach them?, 110
Brett E. Fortune, Lisa M. Forman
- 25** HCV in patients with advanced disease: do you treat them and do you have any caveats?, 115
Gregory T. Everson

Section 2: HBV

- 26** Management of acute HBV, 125
Dennis A. Freshwater, David J. Mutimer
- 27** Rethinking the inactive carrier state: management of patients with low-replicative HBeAg-negative chronic hepatitis B and normal liver enzymes, 129
Ilan S. Weisberg, Ira M. Jacobson
- 28** HBeAg-negative chronic hepatitis B infection with abnormal transaminases and minimal changes on liver biopsy, 135
Graham R. Foster
- 29** Combination therapy for chronic hepatitis B virus infection: should we use it *ab initio* or sequentially?, 138
William Alazawi, Graham R. Foster
- 30** Management of hepatitis B virus infection in pregnancy, 142
Eleri S.W. Wilson-Davies, William F. Carman
- 31** Management of hepatitis B in children, 146
Maureen M. Jonas
- 32** Hepatitis B infection in surgeons and healthcare workers: what should we do to protect patients?, 151
Graham R. Foster
- 33** HBV in the poorly compliant patient: dare we start oral drugs?, 154
Tin Nguyen, Paul Desmond, Stephen Locarnini
- 34** Acute liver failure and HBV: is there a role for HBV therapy?, 159
Hank S. Wang, Tram T. Tran
- 35** High-risk needle exposure in hepatitis B vaccine failures: what are the options?, 163
Pari Shah, Kimberly A. Forde
- 36** Antiviral prophylactic treatment of chronic hepatitis B to prevent viral reactivation during cytotoxic chemotherapy, 168
Mohsin Ali, K. Rajender Reddy
- 37** Management of hepatitis B in HIV-infected and other immunosuppressed patients, 174
Kaiser Raja, Douglas T. Dieterich

- 38** Lamivudine and adefovir resistance: what should we do?, 181
Geoff M. Dusheiko
- 39** HBV therapy following unsuccessful interferon therapy: how do you see the role for oral therapies?, 188
Grace M. Chee, Fred F. Poordad
- 40** Hepatitis B and hepatitis C co-infection, 192
Quentin M. Anstee, Belinda C. Smith, Howard C. Thomas

Part III: Clinical Set-up

- 41** The nurse practitioner and the physician assistant: their role in HCV management, 199
Brenda A. Appolo
- 42** Non-specialist management in general practice of chronic hepatitis C liver disease: cost-effective or foolish cost cutting?, 202
Chris Helen Ford

Part IV: The Future

- 43** The future of HCV therapy: with or without interferon and ribavirin?, 209
Mark Sulkowski
- 44** Protease and polymerase inhibitors for HCV, 214
Christoph Sarrazin
- 45** HCV vaccines: coming soon?, 221
David E. Kaplan
- 46** New drugs for hepatitis B: what is in the pipeline?, 226
Cihan Yurdaydin, A. Mithat Bozdayi, Ramazan Idilman, Hakan Bozkaya
- 47** Hepatitis B – a therapeutic vaccine: hope or hype?, 230
Rosa Di Stefano, Antonio Craxi
- 48** Novel interferons: is there life in the old dog yet?, 236
Graham R. Foster

Part V: Ongoing Controversies

- 49** Is interferon a valuable first-line therapy for HBeAg-positive HBV?, 241
Patrick Marcellin, Rami Moucari, Olivier Lada, Tarik Asselah
- 50** Most patients with hepatitis C will die from their disease, 246
Graham R. Foster, Steven Masson
- 51** Most patients with hepatitis C will die with their disease, 249
Ronald L. Koretz

Index, 252